United Kingdom
The Netherlands, Switzerland, Austria, Italy, Sweden, Denmark, France, Poland
Israel, Greece

News

2017

  • Global press release

    The AIDA project: Optimising the use of old antibiotics to improve patient care

  • Enrollment of patients in the colistin trial is completed. We included 407 critically ill patients with carbapenem resistant Gram-negative pathogens in this randomized controlled trial.

  • ISAP organised a pre-ECCMID conference in Vienna to discuss PK/PD principles for optimising the use of antibiotics.

  • AIDA was covered in national press releases:
     Israel

2016

2015

  • The TATFAR meeting (Transatlantic Taskforce on Antimicrobial Resistance) held a meeting in Luxembourg under the EU presidency of Luxembourg in October to discuss and coordinate activities between the EU, Norway, USA, and Canada focused on keeping antibiotics efective. Ursula Theuretzbacher presented the case of optimising the use old antibiotics and keeping them available for patients in need. AIDA served as model for necessary academic, structured and coordinated "re-development" activities.

  • The Postgraduate Education Course Improving the Dosage of Old Antibiotics has been organised by Johan Mouton and Ursula Theuretzbacher and will take place in Warsaw, Polandon 19-21 November 2015.  Registration is open with the deadline of 5 October 2015.

  • A series of articles has been published in CMI dedicated to the revival and "re-development" of old antibiotics

  • The 2nd International Conference on Polymyxins will take place in San Diego on 22-24 September 2015 in SAn Deigo, CA, USA. AIDA partners Johan Mouton and Ursula Theuretzbacher are members of the Organising Committee and William Couet, Alasdair MacGowan, Mical Paul and Ursula Theuretzbacher are presenting.

  • Press release Chemistry World

2014

  • The results of the Polymyxin conference in Prato, Italy, May 2013 have been published in Lancet Infectious Diseases, 2014, 21st Oct:

    RL Nation, J Li, O. Cars, W. Couet, MN Dudley, KS Kaye, JW Mouton, DL Paterson, VH Tam, U. Theuretzbacher, BT Tsuji, JD Turnidge: Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

  • The AIDA project is ont the HorizonHealth website.    HHlogo with pay off

  • ESCMID conferenceWe are planning a special conference on the AIDA topic: Reviving and redeveloping old antibiotics
    This conference presents and summarises currently available knowledge regarding optimised clinical use of old revived antibiotics and will discuss gaps of knowledge and future areas of research as well as adapting breakpoints, enriching treatment guidelines, and implications for regulatory issues. The major expectation for this conference is to drive the optimised usage of old antibiotics, especially indications and dosage regimens, as a key contribution to preserving the efficacy of these essential drugs in an era of escalating multi-drug resistance.More information

  • website old antibioticsThe new website NEW LIFE FOR OLD ANTIBIOTICS is online! In collaboration with the ESCMID PK/PD study group that has been founded by AIDA partners this website provides a comprehensive resource on old antibiotics. The results from the AIDA project will be an important source for this website. Please contribute to this website with your comments and experiences. The knowledge is about some of the old antibiotics is rapidly increasing while others are still used based on knowledge generated 50 years ago.

2013

  • To explore the available knowledge about the activity of colistin combinations in vitro, partners of WP1 conducted a systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. The clinical trial of WP1 will examine the effect of colistin +meropenem vs colistin alone and thus, provide the required link between in vitro and clinical studies.
    The article has been recently published.

    Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013 Oct;57(10):5104-11.

  • The study Pharmacodynamics of minocycline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection byAR Noel, KE Bowker, S Tomaselli, AP MacGowan - BCARE, Bristol, WW Hope - AP&T, Liverpool has been presented at ICAAC 2013. This PK/PD study will support the clinical study of WP3. Poster

  • June 2013: The WP1 team with Mical Paul as work package leader hast recently started with enrollment of the first patient in the clinical trial. The clini­cal trial is enriched by an extensive pharmaco­kinetic and microbiological assessment of every patient. The resulting data will serve as primary input for the PK/PD modeling effort as well as for a microbiological study that will monitor the influence of antibacterial therapy on the selection of resistant bacteria in clinical samples and body flora.
  • The 1st International Conference on Polymyxins, an opinion-leader conference to present and learn of the latest findings on the polymyxin antibiotics, took place on 2 - 4 May, 2013 at the Monash University Centre in Prato, Italy. The AIDA partners Johan Mouton, Mical Paul, William Couet, Lena Friberg and Ursula Theuretzbacher were instrumental in the organization of the conference and contributed new data and knowledge that was gained since the start of the AIDA project.
    The presentations will be available soon.
  • The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), funds a trial with a comparable goal and protocol. The Principal Investigator is Keith Kaye, M.D., M.P.H., Wayne State University, Detroit. As the number of patients with these difficult to treat infections is limited we aim at pooling data to maximise the impact of the AIDA and the NIH trial. Though the protocols are not identical we make sure to collect the same information for a combined analysis. During the ECCMID in Berlin we had our first official meeting with Dennis M. Dixon, Ph.D., chief of NIAID’s Bacteriology and Mycology Branch and Keith Kaye to discuss challenges and strategies for our future communication and collaboration.

  • The specialised conference Superbugs&Superdrugs in London, March 2013, covered the key topics of discovery and clinical development challenges of novel antibacterial drugs, the EMA approach to regulating antimicrobials, and partnership and funding opportunities in Europe. Ursula Theuretzbacher presented the topic “Publicly funded antibacterial drug development in Europe” and took part in a panel discussion with Line Matthiessen (Head of Infectious Diseases and Public Health Unit, European Commission), Richard Bergstrom (Director General, European Federation of Pharmaceutical Industries and Associations, EFPIA), Richard Bax (TranScrip Partners).
  • The new EMA draft guideline on developing novel antibiotics for patients infected with highly resistant organisms for which there are limited treatment options available is based on only limited evidence of clinical efficacy regardless of the site of infection but on extensive non-clinical evaluation, relevant human pharmacokinetic data, and robust pharmacokinetic/pharmacodynamic analyses. Ursula Theuretzbacher presented the colistin trial (WP1 of the AIDA project) as an example of a clinical study design supported by extensive collection of non-clinical data. Though colistin is an old drug its "re-development" according to modern standard, as designed in the AIDA project, may provide input to the discussion of such new development strategies. The FP7 funded project AIDA aims at demonstrating the value of highly integrated clinical, in vitro, in vivo, and PK/PD data to facilitate the testing of antibiotics in infections caused by multi-drug resistant bacteria.

2012

  • The interest in re-evaluating old antibacterial drugs as last resort drugs against multidrug-resistant pathogens continues. The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is one of the major conferences in the field of antimicrobial drugs. At the ICAAC 2012 in San Francisco about 40 presentations focused on colistin/polymyxinB. Main topics were Whole Body Physiologically Based Pharmacokinetic models to describe human pharmacokinetics of CMS and colistin, pharmacokinetics of nebulized colistin, pharmacokinetics in Cystic Fibrosis, probability of target attainment over time, clinical studies describing colistin combinations and intraventricular therapy, predictors of therapy failure, systematic review of nephrotoxicity, in vitro studies focusing on colistin combinations, methods for MIC testing and time-kill assays, susceptibility surveys, and a new polymyxin formulation (nanoantibiotics dextrin-colistin conjugates).
  • At the ICAAC 2012 the first study of the AIDA project was presented (A-032). The population PK model and sparse sampling strategy will serve as basis for the determination of individual concentration-time profiles in the colistin clinical trial (WP1) for the evaluation of PK/PD-relationships and potential covariate relationships.
  • The first study of the AIDA project has been accepted for presentation at ICAAC 2012 in San Francisco. Lena Friberg's team, partner in WP4, designed a sparse pharmacokinetic sampling strategy of colistin pharmacokinetics. This sparse sampling schedule will be used for the clinical trial in WP1 to help characterizing PKPD relationships in the enrolled critically ill patients. Given a target concentration and a fast method for concentration quantification a similar methodology could be applied to develop a therapeutic drug monitoring sampling schedule.
    A. N. Kristoffersson, J. Nyberg, L. E. Friberg: Optimal Design of a Colistin Sparse Sampling Schedule for individual PK-parameter Estimation. ICAAC 2012.

  • The first symposium that is organised in collaboration with the AIDA project focuses on colistin use in clinical practice. It is part of the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London.

  • The first AIDA general assembly meeting will take place on December 17 and 18 2012. See "events" for more info.

  • There is a vacancy for a PhD student for the AIDA project in the Netherlands. Please find the details in the link: http://www.umcn.nl/WERKENBIJ/Pages/Vacatures.aspx?vacid=5441